Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
American College of Cardiology
Biotech
AZ's oral PCSK9 inhibitor halves bad cholesterol in phase 2
AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial.
James Waldron
Mar 31, 2025 12:00pm
NewAmsterdam shares more data on lipid-lowering Amgen castoff
Apr 9, 2024 5:30am
ACC: Efficacy ticks down a smidge for Ionis' metabolic drug
Apr 7, 2024 9:45am
ACC: Medtronic touts 3-year renal denervation data
Apr 4, 2022 12:45pm
Cytokinetics preps omecamtiv for support role in heart failure
May 17, 2021 8:00am
MyoKardia cuts heart stress signs in biomarker study
Mar 30, 2020 10:30am
